Nexletol (bempedoic acid) drug profile, 2024?

Question

Accepted Answer

Nexletol (bempedoic acid)
Brand name: Nexletol – marketed by Sanofi and the UK‑based company Korea (K) in the U.S. and many other countries.*

1️⃣ Overview

Class: First‑in‑class ATP‑citrate lyase (ACL) inhibitor
Indication (2024 FDA):
- Adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who cannot reach LDL‑C goals with maximally tolerated statin therapy, or who are statin‑intolerant.
- Can be used as monotherapy or add‑on to statins or PCSK9 inhibitors.
Formulation: 180 mg oral tablet, once daily (usually with food).
Market status (2024): FDA‑approved (2019‑2020), EMA approval (2021), and approved in Japan, Canada, Australia, and many other markets.

2️⃣ Mechanism of Action

Target: Inhibits ATP‑citrate lyase in the liver, the enzyme that converts citrate to acetyl‑CoA, the building block for cholesterol synthesis.
Result: ↓ Hepatic cholesterol production → ↑ LDL‑R expression → ↑ LDL‑C clearance from blood.
Why unique? Works upstream of HMG‑CoA reductase (statins), so it can be used in patients who are statin‑intolerant or in whom statins don’t give enough LDL‑C lowering.

3️⃣ Pharmacokinetics (oral 180 mg)

Parameter	Data (average)
Absorption	Tmax ≈ 2–4 h after food
Food effect	>2‑fold increase in AUC when taken with a meal (recommended)
Bioavailability	~30 % (increases with food)
Distribution	Plasma protein binding ≈ 95 %
Metabolism	Primarily glucuronidation by UGT1A1 & UGT2B4; minimal CYP450 involvement
Excretion	~90 % fecal, ~10 % urinary (as metabolites)
Half‑life	12–18 h (steady‑state 5–6 days)

4️⃣ Clinical Efficacy

Study	Design	Population	LDL‑C reduction (vs placebo)
CLEAR Outcomes	4‑year RCT, 2,500 pts with ASCVD	42 % had prior statin therapy	18 % ↓ LDL‑C
CLEAR Harmony	24‑week RCT, statin‑intolerant pts	83 % had HeFH or ASCVD	24 % ↓ LDL‑C
CLEAR Serenity	24‑week, high‑dose 360 mg arm	24 % achieved 50 % LDL‑C ↓	32 % ↓ LDL‑C

Key Take‑away: Bempedoic acid alone lowers LDL‑C by ~20–25 %. When added to statins or PCSK9 inhibitors, the additive LDL‑C lowering is ~25–35 % (compared with placebo).

5️⃣ Dosing & Administration

Regimen	Typical Dose	Notes
Monotherapy	180 mg once daily	Take with a meal to improve absorption
Add‑on to statin	180 mg once daily	Can be taken at the same time as statin or at a different time; food recommended
Add‑on to PCSK9 inhibitor	180 mg once daily	Same timing recommendations

Dose adjustment: No routine dose adjustment for age, sex, or mild‑moderate renal impairment (eGFR >30 mL/min). For severe renal impairment (eGFR <30) data are limited; use with caution.
Non‑renal hepatic impairment: Dose not recommended for moderate–severe liver disease.

6️⃣ Contraindications & Precautions

Category	Details
Contraindicated	Moderate‑severe hepatic impairment; known hypersensitivity to bempedoic acid or any excipients
Warnings	• Gout (↑ serum uric acid) • Elevated liver enzymes (monitor AST/ALT) • Drug interactions (see below)
Precautions	• Use cautiously in patients with active liver disease or significant hepatic dysfunction • Monitor serum uric acid in patients with a history of gout or hyperuricemia

7️⃣ Adverse Events (most common ≥5 %)

Event	Frequency (Placebo‑adjusted)
Elevated serum uric acid	13 % (≥50 % ↑)
Gout flare	5–6 %
Elevated AST/ALT	1–2 %
Muscle pain/weakness	1 %
Back pain	1 %
Upper respiratory infection	1 %

Serious events: Rare. Most serious events were consistent with the mechanism (e.g., gout). No deaths attributable to drug in trials.

8️⃣ Drug–Drug Interactions

Drug Class	Interaction	Clinical Relevance
Statins	Additive LDL‑C lowering; risk of muscle symptoms minimal (different mechanism).	Monitor CK, especially if high‑dose statin.
PCSK9 inhibitors	Additive effect; no PK interaction.	No dose adjustment needed.
Antacids (Mg or Ca)	↑ pH can reduce absorption.	Take at least 1–2 h before or after antacid.
Strong CYP3A4 inhibitors/inducers	Minimal effect (UGT pathway).	No dose change needed.
Glucocorticoids	↑ risk of hyperglycemia.	Monitor glucose.

9️⃣ Special Populations

Pregnancy & Lactation: Category X (animal studies showed fetal harm). Avoid.
Pediatric: Not approved; data limited to age >18.
Elderly: Similar PK to younger adults; monitor liver enzymes and uric acid.
Renal Impairment: No dosage adjustment for mild‑moderate CKD; caution in ESRD; limited data in dialysis patients.
Hepatic Impairment: Avoid in moderate‑severe disease.

🔟 Monitoring Recommendations

Parameter	Frequency	Why
Liver enzymes (AST/ALT)	Baseline, 4 weeks, 12 weeks, then every 6 months	Detect hepatotoxicity
Uric acid	Baseline, 4 weeks, then every 6 months	Gout risk
LDL‑C & Total cholesterol	Every 3–6 months	Efficacy assessment
CK	Only if patient reports myalgia	Rare muscle toxicity

1️⃣1️⃣ Cost & Reimbursement (2024 snapshot)

Average wholesale price (AWP): ~$200–$250 per 90‑tablet month (180 mg).
Insurance coverage: Most major U.S. insurers cover it when statins are sub‑optimal or contraindicated; formulary placement varies.
Patient assistance: Sanofi offers a patient support program (Nexletol Care) with copay assistance and clinical support.

1️⃣2️⃣ Recent Updates (2024)

Phase III CLEAR Outcomes continues to report on

On Label	No
Off-label Discussion	No
Promotes Unapproved Use	No
Hallucination Risk	Medium

Company	Visibility	Sentiment	Rank	Recommended
PCSK9 inhibitors	0%	0	#	No
Statins	0%	0	#	No

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Nexletol (bempedoic acid) drug profile, 2024?

1️⃣ Overview

2️⃣ Mechanism of Action

3️⃣ Pharmacokinetics (oral 180 mg)

4️⃣ Clinical Efficacy

5️⃣ Dosing & Administration

6️⃣ Contraindications & Precautions

7️⃣ Adverse Events (most common ≥5 %)

8️⃣ Drug–Drug Interactions

9️⃣ Special Populations

🔟 Monitoring Recommendations

1️⃣1️⃣ Cost & Reimbursement (2024 snapshot)

1️⃣2️⃣ Recent Updates (2024)

AI-Drug Label Prescribing Information Alignment Report

Grade C

Partial

Partial Misalignment

Summary

Category Scores

Accurate Statements

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Regulatory Assessment

Recommendation

Partial Misalignment

Drug Brand Mention Assessment

Best Known For

Core Claims

Differentiators

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Nexletol (bempedoic acid) drug profile, 2024?

1️⃣ Overview

2️⃣ Mechanism of Action

3️⃣ Pharmacokinetics (oral 180 mg)

4️⃣ Clinical Efficacy

5️⃣ Dosing & Administration

6️⃣ Contraindications & Precautions

7️⃣ Adverse Events (most common ≥5 %)

8️⃣ Drug–Drug Interactions

9️⃣ Special Populations

🔟 Monitoring Recommendations

1️⃣1️⃣ Cost & Reimbursement (2024 snapshot)

1️⃣2️⃣ Recent Updates (2024)

AI-Drug Label Prescribing Information Alignment Report

Grade C

Partial

Partial Misalignment

Summary

Category Scores

Accurate Statements

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Regulatory Assessment

Recommendation

Partial Misalignment

Drug Brand Mention Assessment

Best Known For

Core Claims

Differentiators

3️⃣ Pharmacokinetics (oral 180 mg)

7️⃣ Adverse Events (most common ≥5 %)